2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.Peer-Reviewed Original ResearchPrimary treatment failureAuto-HCTStable diseaseHodgkin lymphomaPartial responseCumulative incidence of non-relapse mortalityIncidence of non-relapse mortalityAssociated with inferior PFSEfficacy of auto-HCTAssociated with inferior OSAutologous hematopoietic cell transplantationEvaluation of prognostic factorsClassical Hodgkin lymphomaNon-relapse mortalityMulticenter retrospective cohortHigh-risk diseaseHematopoietic cell transplantationLong-term efficacyPatterns of failureUS medical centersProgression of diseaseInferior PFSMedian PFSInferior OSComplete response
2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Epperla N, Costa L, Vaughn J, Hanel W, Raya S, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta S, Caimi P, Sethi T, Reddy N, Burkart M, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery L, Lansigan F, Glenn M, Churnetski M, Cohen J, Sorge C, Xavier A. Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. Blood 2019, 134: 1554. DOI: 10.1182/blood-2019-129199.Peer-Reviewed Original ResearchPR/stable diseasePrimary treatment failureClassical Hodgkin lymphomaAnthracycline-containing chemotherapy regimensOutcomes of patientsHigh-dose chemotherapyStable diseaseOverall survivalER cohortComplete remissionSeattle GeneticsSpeakers bureauPP cohortSalvage therapyChemotherapy regimensProgressive diseasePartial responseTreatment failureHodgkin's lymphomaNew agentsAdvanced-stage classical Hodgkin lymphomaFive-year overall survivalRelapsed classical Hodgkin lymphomaAutologous hematopoietic cell transplantationRefractory classical Hodgkin lymphoma
2015
Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma
Sethi T, Nguyen V, Morgan D, Greer J, Reddy N. Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma. Blood 2015, 126: 2640. DOI: 10.1182/blood.v126.23.2640.2640.Peer-Reviewed Original ResearchProgression-free survivalAbsolute lymphocyte countClassical Hodgkin lymphomaNodular sclerosis Hodgkin lymphomaSuperior progression-free survivalOverall survivalHodgkin's lymphomaLymphocyte countAdvanced-stage Hodgkin lymphomaMixed cellularity Hodgkin's lymphomaCompletion of chemotherapyInitial chemotherapy treatmentMedian overall survivalAdvanced stage diseaseCompletion of therapyFirst-line chemotherapyStage Hodgkin lymphomaKaplan-Meier methodPredictors of survivalImmune effector cellsLog-rank testTime of apheresisNew therapeutic agentsTerms of histologyALC recovery